医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Scarlet and Sylfirm X Gain Momentum as Serendia Reaches Settlements in ITC Patent Infringement Case for the Benefit of Viol

2024年06月19日 PM03:20
このエントリーをはてなブックマークに追加


 

SEONGNAM, South Korea

As the US International Trade Commission (USITC) prepares to announce its final determination on July 9th, Viol’s US distributor Serendia LLC are pleased to report significant progress in their patent infringement litigation. Several leading medical device companies have settled, recognizing the originality and innovation of Viol’s RF microneedling products, including Scarlet and Sylfirm X.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618176340/en/

Viol’s Scarlet and Sylfirm X devices utilizing patented Na Effect technology (Photo: Viol)

Viol’s Scarlet and Sylfirm X devices utilizing patented Na Effect technology (Photo: Viol)

Major Settlements and Ongoing Investigations

The USITC’s ongoing probe has led to settlements with major companies accused of infringing Viol’s patents. Rohrer Aesthetics LLC, Lutronic Corporation, SHEnB Co. LTD, Aesthetics Biomedical Inc., and Ilooda Co. Ltd. have agreed to undisclosed settlements, validating the strength and credibility of Viol’s patented microneedle RF technology. Despite these significant settlements, Jeisys Medical Inc. and EndyMed Medical Ltd. remain under investigation. The implicated products in these infringement cases include well-known devices such as Vivace, Virtue RF, GENIUS, PiXel8, Secret and SecretPRO, Intensif, and Potenza.

Global Recognition of Technological Excellence

The recent settlements not only underscore the innovative nature of Viol’s RF microneedling technology but also highlight the global acknowledgment of Viol’s pioneering advancements. The patented “Na Effect” technology, utilized in Scarlet and Sylfirm X, is celebrated for its precision in delivering high-frequency energy to the dermis, enhancing collagen production while minimizing damage to the epidermis. This breakthrough method offers significant clinical benefits, including reduced pain and downtime for patients.

Market Growth and Future Potential

These settlements place Viol (KOSDAQ:335890) in a strong position to capitalize on the rapidly growing global market for energy-based aesthetic devices. The aging population’s increasing desire to maintain a youthful appearance has led to a surge in non-surgical cosmetic procedures, including fat reduction, skin tightening, and anti-aging treatments. This trend is driving substantial growth in the market, utilizing technologies such as lasers, radiofrequency, and ultrasound.

Technological advancements are broadening the capabilities of energy-based aesthetic devices, enabling a wider range of safe and effective treatments with minimal downtime and discomfort for patients. The global market for these devices is projected to grow at a rate of 10% per year, reaching $7.3 billion by 2025. Korean medical device manufacturers, known for their cost efficiency and cutting-edge technology, are well-positioned to excel in this expanding market, making their devices highly attractive to aesthetics practitioners worldwide.

Implications on Market Dynamics and Innovation

Viol’s successful defense of its patents and the resultant settlements with industry giants reinforce its leadership in the beauty medical device sector. This achievement underscores the company’s commitment to technological advancement and the protection of its intellectual property rights, ensuring the continued dominance of its RF microneedling products in the market.

Continued Innovation and Future Outlook

As Viol continues to advance its RF microneedling technology, the recent settlements set a strong precedent for its dedication to safeguarding intellectual property while providing cutting-edge solutions in aesthetic dermatology. Backed by robust US patents, Scarlet and Sylfirm X remain at the forefront of skin treatments, offering unparalleled clinical advantages and solidifying Viol’s status as a market leader.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618176340/en/

CONTACT

Viol Co., Ltd.

Carly Song +82 70-4454-5718

info@scarletrf.com

同じカテゴリーの記事 

  • Kolmar BNH Expedites European Market Expansion with its Technology-Driven HemoHIM G
  • Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
  • Fast Company Magazine Awards Xenco Medical with 2024 Innovation by Design Award for the TrabeculeX Continuum
  • PROTEINA Co., Ltd. Announces Breakthrough Research Published in Nature Biomedical Engineering
  • InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.